FDA approves Xofigo for advanced prostate cancer

The US Food and Drug Administration (FDA) has approved Xofigo (radium-223 dichloride) to treat certain men with advanced prostate cancer. It is intended for men whose cancer has spread (metastasized) only to their bones and who have already received treatment to lower testosterone. Read more here.